| Literature DB >> 32803687 |
Samapika Nandy1, Abhijit Dey2.
Abstract
BACKGROUND: The amphibian, non-vascular, gametophyte-dominant, bio-indicator class, bryophytes; with their wide ranges of habitat have attained importance due to their promising medicinal attributions and therapeutic role; mostly aided by presence of aromatic bibenzyl and bisbybenzyl class of compounds. Bibenzyls are steroidal ethane derivatives, resembling the structural moiety of bioactive dihydro-stilbenoids or iso-quinoline alkaloids. These stress triggered secondary metabolites are the by-products of the flavonoid biosynthetic pathway. Different classes of bryophytes (Bryophyta, Marchantiophyta and Anthocerotophyta) possess different subtypes of bibenzyls and dimeric bisbibenzyls. Among the liverwort, hornwort and mosses, former one is mostly enriched with bibenzyl type constituents as per the extensive study conducted for phytochemical deposit. Considering macrocyclic and acyclic group of bibenzyls and bisbybenzyls, generally marchantin type compounds are reported vividly for significant biological activity that includes neuro-nephro-cardio-protection besides anti-allergic, anti-microbial, anti-apoptotic and cytotoxic activities studied on in-vitro and in-vivo models or on cell lines. RESULT: The critical analysis of reported chemical and pharmaceutical attributions of bibenzyls and bis-bibenzyls yielded detailed report on this compound class along with their application, mode of action, natural source, techniques of synthesis, extraction procedure, isolation and characterization. Further, the structure activity relationship studies and bioactivity of bibenzyls derived from non-bryophytic origin were also summarized.Entities:
Keywords: anti-apoptotic; anticancer; bibenzyls; bisbybenzyls; marchantin; riccardin
Year: 2020 PMID: 32803687 PMCID: PMC7429097 DOI: 10.1007/s40199-020-00341-0
Source DB: PubMed Journal: Daru ISSN: 1560-8115 Impact factor: 3.117
Fig. 1Habits of few bioactive bryophytes; a. Bazzania trilobata, b. Blasia pusilla c. Radula complanata d. Riccardia multifida, e. Marchantia paleacea, f. M. polymorpha, g. M.papillata, h. Dumortiera hirsuta
Bioactivity of bibenzyls with their source(s), experimental organism and/or cell line(s)
| bioactivity | name of the compound | source bryophyte | family of the bryophyte | experimental organism/cell line | experimental outcome | experimental details | mechanism of action | reference |
|---|---|---|---|---|---|---|---|---|
| cytotoxicity, pro-apoptotic, MDR reversal activity | brittonin A | Frullania | KB | ID50 42.1 ± 2.51 μM | determination of melting points, optical rotation, CD spectra, IR spectra, NMR spectra and HPLC | reversal of adriamycin resistance | [ | |
| KB/VCR | ID50 33.7 ± 1.28 μM | |||||||
| K562 | ID50 49.6 ± 3.13 μM | |||||||
| K562/A02 | ID50 30.9 ± 2.59 μM | |||||||
| brittonin B | KB | ID50 24.4 ± 1.11 μM | ||||||
| KB/VCR | ID50 26.3 ± 1.77 μM | |||||||
| K562 | ID50 42.8 ± 3.11 μM | |||||||
| K562/A02 | ID50 21.0 ± 1.91 μM | |||||||
| cytotoxic activity | chrysotobibenzyl | Frullania | human cell lines (KB KB/VCR K562 and K562/A02) | ID50 11.3 ± 1.43 μM, 12.8 ± 1.53 μM, 14.5 ± 1.94 μM and 12.0 ± 2.45 μM respectively | spectral analysis, NMR and HPLC study | MDR reversal | [ | |
| pro-apoptotic activity | dihydroptychantol A | chemically synthesized (natural source: | Aytoniaceae | human osteosarcoma U2OScells | IC50 29.6 μM (24hr), 24.7μM (48 hr) | cytotoxicity assay using time-lapse microscopic studies, TEM, AO and DAPI staining, apoptosis and cell cycle distribution study by FACS, RT-PCR | autophagy induction, upregulation of cyclin B1 and nuclear p53, expression, downregulation of cytoplasmic p53, G2/M cell cycle arrest | [ |
| human glioblastoma U87 cells | IC5021.2 μM (24hr), 23.7 μM(48 hr) | MDR reversal of chemoresistant cell line | ||||||
| cytotoxic activity | lunularin | Marchantiaceae | human HepG2 cell line, | IC50 7.4 mg/ml | FT-IR spectroscopy, NMR, column chromatography | [ | ||
| anti-cancer activity | marchantin A | Marchantiaceae | Human MCF-7 | IC50 4.0 μg/ml | reversed-phase HPLC/UV, morphological study of apoptosis and cell cycle study using annexin V-FITC staining, densitometricanalysis, RT-PCR, FACS and western blot screening | dose and time dependent apoptotic induction, upregulated expression of p21 and p27 gene, reduced cyclin B1 and D1 gene expression | [ | |
| cytotoxic activity | marchantin A | Marchantiaceae | rat myeloblastCC50 L6 | IC50 6.64 μM (standard: podophyllotoxin) | resazurin staining, spectrophotometric study, micro-titre plate assay | enzyme inhibition, anti-oxidant activity | [ | |
| anti-proliferation activity | marchantin C | Schistochilaceae | P388 leukemia cells | IC508.5 μg/ml. | bioactivity-guided isolation, cytotoxic assay | cytotoxicity | [ | |
| pro-apoptotic activity | marchantin M | Aytoniaceae | PC3 | IC505.45 μM/l | cytotoxicity assay via MTT and Western blotting. FACS, morphological investigation performed to study cell cycle regulation and apoptosis induction | caspase-3 activation, induction of PARP cleavage | [ | |
| cytotoxic activity | neomarchantin A, neomarchantin B | Schistochilaceae, | P388 | IC5018 and 7.6 μg/ml respectively | bioactivity-guided isolation, cytotoxic assay | apoptosis induction | [ | |
| pro-apoptotic activity | pakyonol | Plagiochaceae | PC3 | IC507.98 μM/l | cytotoxicity study, screening of pro-apoptotic mechanism | growth arrest | [ | |
| cytotoxic activity, anti-tumor activity | pallidisetin A, pallidisetin B | Polytichaceae | human melanoma RPMI-7951 and human glioblastoma U-251 | ED501.0 μg/ml and 2.0 μg/ml respectively (for both cell line) | stereochemistry based study and cytotoxicity assay | growth arrest | [ | |
| pro-apoptotic activity | plagiochin E | Marchantiaceae | chromatin condensationmetacaspase activation, phosphatidylserine exposure increased many fold | TEM, PI, DAPI, FITC-annexin V and FITC-VAD-FMK staining based cytotoxicity dcreening | G2/M cell cycle arrest, chromatin condensation, nuclear fragmentation, downregulated CDC28, CLB2, CLB4 expression, cytochrome c release, metacaspase activation | [ | ||
| MCF-7, PC3and KB | IC5034.9 ± 1.32 μM, 28.0 ± 1.86 μM, 40.1 ± 1.52 μM respectively | immunofluorescence microscopy, molecular modeling, MTT assay | cell cycle arrest, microtubule depolymerization | [ | ||||
| anti-cancer activity | riccardin C | Aytoniaceae | PC3 | IC503.22 μM/L | MTT, western blot, FACS and morphological screening was performed | inhibited cell proliferation | [ | |
| MDR reversal, anti-proliferative activity | riccardin D | Marchantiaceae | HUVEC | CGI 2.2% -28.5% after 72 hr. (applied concentration 2.5-30μM | scratch assay,capillary tube formation assay,cell proliferation assay, western blot, RT-PCR, immunohistochemical staining, MTT assay performed | tumor angiogenesis prevented, VEGF level decreased, blood vessel formation inhibited | [ | |
| pro-apoptotic, topomerase-II inhibitory activity | HL-60, K562 and MDR K562/A02 | IC50 25.2 μM, 21.7 μM and 27.2 μM respectively (after 72 hr) | MTT, UV transilluminator based DNA fragmentation detection, Topo-I and Topo-II mediated supercoiled pBR322 DNA relaxation assay, FITC-Annexin V and PI staining, RT-PCR based expression analysis | [ | ||||
| chemotherapeutic MDR reversal activity | 2-Amino-thiazole derivative of DHA | chemically synthesized | NR | K562 | 11.56% inhibition | cytotoxicity assay, TEM, FACS, RT-PCR, AO and DAPI staining | reversal of vincristine and adriamycin toxicity | [ |
| K562/A02 | 10.11% inhibition | |||||||
| KB/VCR | 0.135 ± 0.009 ID50μM | |||||||
| 2-Amino-thiazole derivative of dimethyl ether of DHA | chemically synthesized | NR | K562 | 58.67 % inhibition | ||||
| K562/A02 | 26.81 % inhibition | |||||||
| KB/VCR | 0.152 ± 0.003 ID50μM | |||||||
| 2-Hydrazino-thiazole derivative of dimethyl ether of DHA | chemically synthesized | NR | K562 | 32.07 % inhibition | ||||
| K562/A02 | 18.76 % inhibition | |||||||
| KB/VCR | 0.176 ± 0.016 ID50μM | |||||||
| cytotoxic activity | 3,3’,4,4’-tetramethoxybibenzyl | Frullania | KB | ID50 30.8 ± 1.74 μM | determination of optical rotation, melting points, CD, IR and NMR spectra, HPLC | reverted adriamycin cytotoxicity | [ | |
| KB/VCR | ID50 >50 μM | |||||||
| K562 | ID50 >50 μM | |||||||
| K562/A02. | ID50 39.2 ± 1.83 μM | |||||||
| cytotoxic activity | 3,5-dihydroxybibenzyl | Radulaceae | HepG-2 | IC50 19.1μg/ml | cytotoxic assay, MTT | Inhibition of cell viability | [ | |
| A549 | IC5016.55 μg/ml | |||||||
| SMMC-7721 | IC5018.49 μg/ml | |||||||
| chemotherapeutic activity | 7-Hydroxyl-8-bromo derivative of dimethyl-ether of DHA | chemically synthesized | NR | K562 | 38.55 % inhibition | cytotoxicity assay, cell cycle study, TEM based microscopic observation | reversal of drug resistance | [ |
| K562/A02 | 11.86 % inhibition | |||||||
| KB/VCR | 0.177 ± 0.012 ID50μM | |||||||
| cytotoxic activity | 14-hydroxylunularin | Ricciaceae | NCTC-Clone 929 fibroblast | cytotoxicity percentage ± SDare 7.91±2.89, 18.88±3.25, 1.40±0.9 respectively at 21.7μM | growth inhibition of cancer cell lines | [ | ||
| J 774 murine macrophage | ||||||||
| peritoneal macrophage (BALB/c mice) | ||||||||
| glioma cell-induced angiogenesis inhibhition | marchantin C | Schistochilaceae | human malignant glioma (T98G) and U87 glioma | 57% inhibition of T98G induced tube formation, 2-fold sFlt-1 level uplift | tube formation assay, ELISA | microtubule depolymerization, cell invasion blocked, inhibition of cellular migration | [ | |
| prevention of intestinal polyposis | riccardin D | Marchantiaceae | male | polyp number reduction 79.3% in colon, downregulation of β-catenin and cyclin D1 expression | immunohistochemical staining, western blotting, (RT-PCR, ELISA | anti-angiogenesis | [ | |
| inhibition of tubulin polymerization | isoplagiochin A , isoplagiochin B | Plagiochilaceae. | Tubulin | IC50 50 and 25 μM respectively | MC conformational search, NMR, spectrophotometric study | cytotoxicity | [ | |
| anti-radical, anti-oxidant | radulanin K | Radulaceae | guinea pig macrophage | IC506μg/ml | radical scavenging assay | Inhibited superoxide anion radical release | [ | |
| paleatin B | Marchantiaceae | IC5011.7 μM/l | arachidonic acid peroxidation assay | enzymatic inhibition | [ | |||
| marchantin A | Marchantiaceae | NO inhibition | EC50 20 lg/ml | DPPH radical scavenging | prevented release of superoxide radical | [ | ||
| marchantin H | Plagiochaceae | rat brain | IC50 0.51±0.03 μM | prevented lipid peroxidation, reduced cytochrome c release | [ | |||
| nitric oxide inhibitory activity | 2-geranyl-3,5-dihydroxybi-benzyl | Radulaceae | lipopolysaccharide stimulated RAW 264 | IC50 4.5 μM | cell culture assay | [ | ||
| anti-bacterial activity | lunularin | Marchantiaceae | MIC 64 mg/ml. | anti-bacterial assay | [ | |||
| 2,4,6-trichloro-3-hydroxybi- benzyl, 2,4-dichloro-3-hydroxybibenzyl, 2-chloro-3-hydroxybibenzyl | Aneuraceae | ZOI 2mm | disk diffusion assay | [ | ||||
| anti-influenza | marchantin E | Frullaniaceae | H3N2, H1N1 influenza A and B viruses | strongest growth inhibition at 50 μM | PA endonuclease inhibition assay, anti-influenza A virus assay, docking simulation | viral growth inhibition | [ | |
| 5-lipoxygenase and cyclooxygenase inhibition | paleatin B | Marchantiaceae | IC500.78 and 45.2 μM/l respectively | reversed-phase-HPLC based analysis; positive control nordihydroguaiaretic acid and indomethacin respectively | exerted lipophilicity, enzymatic inhibition, radical scavenging | [ | ||
| leishmanicidal | 14-hydroxylunularin | Ricciaceae | 100% percentual lysis (control Resveratrol) | growth inhibition | [ | |||
| anti-feedant | 2,6,3′-trichloro-3-hydroxy-4′-methoxybibenzyl, 2,4,6,3′-tetrachloro-3,4′-dihydroxybibenzyl | Riccardiaceae | e | moderate activity | disk-choice bioassay | growth inhibition | [ | |
| anti-fungal | Asterelin A, Asterelin B, | Aytoniaceae | MIC 128 and 512 μg/ml respectively (standard: Fluconazole) | bioautographic assay, microdilution method | growth inhibition | [ | ||
| bazzanin B, | IC50 17.5, 18.9, 3.9, 23.5 μg/ml respectively | microliter plate test, bioautography assay, anti-fungal glass house test | growth inhibition of spore suspension, disease development reduced | [ | ||||
| bazzanin S | IC5030.8, 50.6, 2.6, 4.5 and 29.2 μg/ml respectively (standard: folicur, rovral,amistar) | |||||||
| isoplagiochin D | IC5013.0, 7.6, 4.0,15.9 μg/ml respectively | bioautography assay, microliter plate test, anti-fungal glass house test | growth inhibition, disease development reduced | [ | ||||
| riccardin D | Marchantiaceae | MID 0.4 μg, (standard: miconazole) | bioautography assay | inhibition of fungal growth | [ | |||
| marchantin H | Plagiochaceae | 256 μg/ml | microdilution method | drug resistance reversed | [ | |||
| 11-O-demethyl marchantin I | Aytoniaceae | MIQ 0.4 μg, MIC 64 μg/ml | microdilution method, bioautographic assay | growth inhibition | [ | |||
| marchantin A | Marchantiaceae | MID 2.5 μg | bioactivity-guided fractionation, anti-fungal assay (standard miconazole) | growth inhibition | [ | |||
| 2,6-dichloro-3-hydroxy-4′-methoxybibenzyl. | LC500.44 ppm (average) | brine shrimp lethality bioassay | growth inhibition | [ | ||||
| 4-hydroxy-3’-methoxybibenzyl | Plagiochaceae | MFC 62.5μg/ml | disk assay | growth inhibition | [ | |||
| 13,13’- | Marchantiaceae | MID 0.25 μg/ml (standard : miconasole) | disk assay | growth inhibition | [ | |||
| anti-dermatophyte | 4-hydroxy-3’-methoxybibenzyl | Plagiochaceae | MIC 125μg/ml | disk assay | growth inhibition | [ | ||
| fluconazole reversal activity | plagiochin E | synthetic compound | NR | FIC 0.3125 to 0.375; MIC 16,16,16,32 μg/ml respectively (without fluconazole) | drug pump efflux using Rhodamine 123 efflux, Overexpression study of MDR gene CDR1 | drug refrectory activity | [ | |
| anti-biofilm formation | riccardin D | Marchantiaceae | MIC90 16 μg/ml; | anti-fungal Susceptibility Test, RT-PCR, FM | downregulation of HR genes (EFG1, HWP1, ALS3), growth inhibition | [ | ||
| downregulation of HR genes (ALS1, ALS3, CDC35, ECE1, HWP1,EFG1) | RT-PCR, SEM, CLSM, fluconazole. XTT reduction assay | [ | ||||||
| anti-trypanosomal activity | plagiochin A | Plagiochilaceae | T. bruceibrucei (strain GUTat 3.1) | IC50 0.93 μg/ml (standard: Eflornithine, Suramin) | cytotoxicity | [ | ||
| 2(R)-2-isopropenyl-6,7- dihydroxy-4-(2-phenylethyl) dihydro-benzofuran | Radulaceae | IC50 0.44 μg/ml (standard: Eflornithine, Suramin) | [ | |||||
| anti-protozoal activity | marchantin A | Marchantiaceae | IC50 3.41 μM | growth inhibition, enzymatic regulation | [ | |||
| IC50 2.09 μM | ||||||||
| IC50 14.90 μM | ||||||||
| IC50 1.59 μM | ||||||||
| nematocidal activity | 3-Methoxy-4-hydroxybibenzyl | Plagiochilaceae | IC50 0.13 mg/ml | larval motility inhibition assay | viability reduced | [ |
bibenzyl and derivatives isolated from non-bryophytic origin
| name of the compound | source organism | plant family | Category | plant part used | biological activity | animal model/cell line/assay type | isolation and identification performed by using | reference |
|---|---|---|---|---|---|---|---|---|
bambusifolol, 3-hydroxy-5-methoxy bibenzyl | Orchidaceae | angiosperm | whole plant | cytotoxic | HL-60, SMMC-7721, A-549, MCF-7 and SW-480 | spectroscopic analysis | [ | |
| bulbotetusine | Orchidaceae | angiosperm | tuber | cytotoxic | human tumor cell lines | sephadex LH-20 column chromatography, NMR | [ | |
| Chrysotoxine | Orchidaceae | angiosperm | stem | cytotoxic | H460 , H23 cell lines | HPLC, NMR | [ | |
| neuroprotective | SH-SY5Y cells | [ | ||||||
| dendrosignatol | Orchidaceae | angiosperm | whole plant | cytotoxic | MDA-231, HepG2 and HT-29 | Spectroscopic analysis and MS | [ | |
| dendrowillol A | Orchidaceae | Angiosperm | whole plant | Cytotoxic | HL-60 | spectroscopic analysis | [ | |
| gavilein | (Comm. ex Pers.) M.D. Correa | Orchidaceae | angiosperm | stem | anti-fungal, leishmanicidal | 1D and 2D NMR, UV, IR and HRESIMS. | [ | |
| gigantol | Rchb. f. | Orchidaceae | angiosperm | whole plant | anti-metastasis | H460 cells | HPLC and NMR spectroscopy | [ |
moscatilin (4,40 -dihydroxyl-3,30 ,5- trimethoxybibenzyl) | Orchidaceae | angiosperm | stem | anti-mutagenic | umu gene ( | silica gel CC, EI-MS, 1H and 13C NMR | [ | |
| Orchidaceae | angiosperm | stem | anti-cancer | HUVECs | Silica gel CC, IR-spectroscopy, MS, NMR | [ | ||
| nobilin D, nobilin E | Orchidaceae | angiosperm | stem | anti-oxidant | DPPH assay | spectroscopic analysis | [ | |
| perrottetin H | (Bosch) Baker | Hymenophyllaceae | pteridophyte | whole plant | NM | NM | HPLC | [ |
gigantol , batatasin III, 4¢- hydroxy-3,3¢,5-trimethoxybibenzyl, 3,3¢,4¢,5-tetramethoxybibenzyl , 3,4¢-dihydroxy-5-methoxybibenzyl , 3¢-O-methylbatatasin III, 3,3¢,5-trihydroxybibenzyl, and 3,4¢,5-trihydroxybibenzyl, | Orchidaceae | angiosperm | whole plant | herbicidal | bioassay-guided fractionation | [ | ||
| stilbostemin B 3′-â-D-glucopyranoside, stilbostemin H 3′-â-Dglucopyranoside, and stilbostemin I 2′′-â-D-glucopyranoside | Stemonaceae | angiosperm | root | neuroprotective | SH-SY5Y cell | HPLC | [ | |
| 2-[4-hydroxy-3-(4- hydroxyphenyl) benzyl]-4-(4- hydroxyphenyl) phenol (20C) | Orchidaceae | angiosperm | NM | neuroprotective | MPTP/p mouse model | NM (reagent purchased) | [ | |
| 4,5,4’-trihydroxy-3,3’-dimethoxybibenzyl | Orchidaceae | angiosperm | whole plant | anti-proliferation | H292 cell line | VLC, MPLC, NMR, UPLC-MS | [ | |
| Orchidaceae | angiosperm | Stem | anti-oxidant | DPPH assay | VLC, spectral analysis | [ | ||
| shuangshencaosu 2,2-dimethyl-5-methoxy-7-[2-(3″-hydroxyphenyl)ethyl]chromene | (Rolfe) Tang & F.T. Wang | Orchidaceae | angiosperm | tuber | not evaluated | NM | CC | [ |
| 5-(2,3-dimethoxyphenethyl)-6-methylbenzo[d][1,3]dioxole, dibenz [b, f]oxepine, 10,11-dihydro-2,7-dimethoxy-3,4-methylene-dioxy dibenzo[b, f]oxepine | Orchidaceae | angiosperm | stem | cytotoxic | HeLa cell line | 2D-NMR | [ |
AO: Acridine orange, CGI: cell growth inhibition, CLSM: Confocal laser scanning microscopy, DAPI: 4′, 6-diamidino-2-phenylindole, FIC: fractional inhibited concentration, FITC: fluorescein isothiocyanate, FM: Fluorescence Microscopy, HR gene: Hyphae Related gene, MC: Monte Carlo, MFC: minimum fungicidal concentration, MPLC: medium pressure liquid chromatography, NR: not required, PI: propidium iodide, SEM: Scanning electron microscopy, SD: standard deviation, VLC: vacuum-liquid chromatography
Fig. 2Structures of bioactive bibenzyls: 1.Asterelin A (C28H22O4) 2.Bazzanin S (C28H23ClO4) 3.Brittonin A (C20H26O6) 4.Chrysotobibenzyl (C19H24O5) 5.Isoplagiochin A (C28H22O4) 6.Isoplagiochin B (C28H22O5) 7.Lunularin (C14H14O2) 8.Marchantin A (C28H24O5) 9.Marchantin C (C28H24O4) 10.Marchantin E (C29H26O6) 11.Pakyonol (C29H26O4) 12.Pallidisetin A 13.Pallidisetin B (C23H18O3) 14.Plagiochin A (C29H26O6) 15.Riccardin C (C28H24O4) 16.2-chloro-3-hydroxybibenzyl (C14H13ClO)